Resistance to Lamivudine in HBV Egyptian Patients

Ain Shams University230 enrolled

Overview

On treatment parameters for Lamivudine resistance in HBV treated Egyptian patients

Primarily: To study the correlations between the following parameters in adult Egyptian patients with chronic viral hepatitis B before treatment: * ALT. * HBeAg. * HBV-DNA by quantitative PCR. * Biopsy (if possible). Secondarily: After receiving lamivudine therapy we will identify the impact of these parameters on viral breakthrough at 1 year of therapy.

Study Type

OBSERVATIONAL

Enrollment

230

Conditions

Chronic Hepatitis B Virus Treatment

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients \>18 years old * Egyptian nationality * Positive serology for HBsAg for more than 6 months * Positive HBV viremia (above 2000IU/ml). * Lamivudine monotherapy Exclusion Criteria: * Anti-HBcIgM seropositivity * Positive serology for HCV * Positive serology for HDV * Patients complicated with HCC

Locations (1)

Tropical medicine department

Cairo, Egypt

Outcomes

Primary Outcomes

Resistance to Lamivudine Therapy

Prevelance of Lamivudine resistance among HBV Egyptian cases pretreatment and on treatment parameters for Lamivudine therapy resistance

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.